Counterfeit semaglutide linked to severe adverse events in EudraVigilance real-world safety data

The global demand for semaglutide, a potent GLP-1R agonist used for type 2 diabetes and obesity, has unfortunately fueled a rise in counterfeit products. These illicit versions often lack the active pharmaceutical ingredient, contain incorrect dosages, or are contaminated with harmful substances, posing substantial public health risks. Unlike authentic medications, the safety profile of counterfeit semaglutide is largely unknown, making systematic monitoring crucial. This study addresses the critical gap in understanding the real-world adverse events associated with unapproved semaglutide products.

Researchers conducted a retrospective analysis of real-world safety data from EudraVigilance, the European database for suspected adverse drug reactions. The study aimed to identify and characterize adverse events specifically associated with counterfeit semaglutide products. Data were extracted and analyzed to understand the types, severity, and frequency of reported adverse reactions linked to unverified semaglutide sources. The methodology involved querying the database using keywords related to counterfeiting and semaglutide use, followed by a detailed review of the identified reports.

The analysis of EudraVigilance data revealed a concerning safety profile associated with counterfeit semaglutide. While specific numerical findings are not provided in the abstract, the study identified various adverse event reports linked to these unverified products. These reports often described reactions that were more severe or atypical compared to the known profile of authentic semaglutide. The investigation highlighted that counterfeit products frequently contained either no active semaglutide, incorrect dosages, or undeclared substances, leading to unpredictable and potentially dangerous health outcomes. The types of adverse events reported included gastrointestinal disturbances, such as severe nausea and vomiting, as well as more serious systemic issues like hypoglycemic episodes and cardiovascular events. The overall safety landscape for counterfeit semaglutide was found to be significantly compromised, emphasizing the risks of using unregulated sources.